RxDoctor Payments Data

Randy Rowlands, MD

Internal Medicine · Ocean, NJNPI 1417156514

Payments from drug & device makers

$1,384in general payments, 2019–2025

Across 43 payments — averaging $32.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$753
  • AbbVie$141
  • Viatris Specialty LLC$112
  • La Jolla Pharmaceutical Company$85
  • Exact Sciences$74
  • Lilly USA, LLC$54
  • plus $164 from 8 others

What the payments were for

  • Food & beverage$1,384100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,384 in reported general payments places this provider in the 70th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$151,768
Medicare patients
503
Services billed
1,852

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide57$76,726
EliquisApixaban63$70,881
FarxigaDapagliflozin Propanediol55$62,010
JanuviaSitagliptin Phosphate52$54,896
MounjaroTirzepatide36$44,955
TrulicityDulaglutide30$37,660
LinzessLinaclotide36$29,728
JardianceEmpagliflozin11$16,927
VascepaIcosapent Ethyl11$10,870
Breo ElliptaFluticasone/Vilanterol20$10,162
Fluticasone-SalmeterolFluticasone Propion/Salmeterol33$9,402
Atorvastatin Calcium566$6,655
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$6,012
Rosuvastatin Calcium277$5,734
Valsartan128$4,422

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$54$82,61566 claims
Novo NordiskOzempic$33$76,72657 claims
AstraZenecaFarxiga$753$62,01055 claims
AbbVieLinzess, Synthroid$141$33,45279 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Ocean

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →